Cartesian Therapeutics, Inc.
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
RNAC | NDAQ
Overview
Corporate Details
- ISIN(s):
- US8162121045
- LEI:
- Country:
- United States of America
- Address:
- 7495 NEW HORIZON WAY, 21703 FREDERICK
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of mRNA-engineered cell therapies. The company focuses on treating autoimmune diseases by leveraging its novel mRNA platform to create targeted and controlled cell therapies. This innovative approach is designed to expand the reach of cell therapy beyond its traditional applications, offering potential treatments that can be administered in an outpatient setting. Cartesian is advancing a pipeline of clinical assets for various autoimmune conditions, with its lead candidate being Descartes-08.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cartesian Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cartesian Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cartesian Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
